Dr. Primo Nery Lara Jr., MD

Dr. Lara practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Dr. Lara's NPI, 1972585743, was assigned on November 17, 2005. Dr. Lara graduated from University of the Philippines College of Medicine in 1992. Dr. Lara holds California license A55072.

Dr. Lara's primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Dr. Lara's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. Dr. Lara is also affiliated with Marshall Medical. The medical group on file is UC Davis Medical Group. Dmand AI also links Dr. Lara to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lara practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Lara's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Lara is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Lara's licenses on file in 2 states: California and Illinois.

Dmand AI lists lung cancer and prostate cancer among the conditions Dr. Lara treats.

CMS data shows 244 Medicare services from Dr. Lara across 4 procedure codes in 2024, for 77 Medicare patients. Medicare paid $12,451 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 77 Medicare patients who saw Dr. Lara in 2024. The largest group is 75 to 84, with 31 patients. 75% of them have cancer, and 75% have high blood pressure. 16% are also on Medicaid. Their average risk score is 2.87, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lara's median patient age at 74, with 23% women.

In 2024, Dr. Lara wrote 218 Medicare Part D claims for 37 patients. 52% of them were for generic drugs. CMS names the drug for 188 of them, across 9 drugs with 11 or more claims each, at $1,371,445 in total drug cost. In 2023, CMS named 165 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Lara for performance year 2024, reported as part of a group. Dr. Lara accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lara as offering telehealth.

Dmand AI links 217 papers to Dr. Lara, published from 2003 to 2025. 2019 was the busiest year, with 13. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Lung Neoplasms and Carcinoma, Non-Small-Cell Lung. Dr. Lara has published most often in Clin Lung Cancer. Dr. Lara's most frequent co-authors are Christopher P. Evans, MD, David Raymond Gandara, MD and Derick Hon Man Lau, MD, PhD.

Dmand AI links Dr. Lara to 36 clinical trials, 21 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Carcinoma, Renal Cell. National Cancer Institute (NCI) sponsors the most, 9.

CMS Open Payments shows 133 general payments to Dr. Lara from 20 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 77% of the total. Genentech, Inc. paid the most, $25,399. It also lists 12 research payments totaling $7,218 in 2016.

Dmand AI lists 2 awards for Dr. Lara, most recently CMS Stage 1 EHR in 2012.

Dr. Lara graduated from University of the Philippines College of Medicine in 1992.

Dr. Lara is in network with 10 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.